Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 5Triple Negative Breast Neoplasms 4Neoplasm Metastasis 4Lymphoma 4Carcinoma, Non-Small-Cell Lung 4Neuroblastoma 3Melanoma 3Lung Neoplasms 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Neoplasms 2Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Lymphoma, Follicular 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Gliosarcoma 2Glioma 2Glioblastoma 2Carcinoma, Renal Cell 2Brain Neoplasms 2Astrocytoma 2Advanced Malignant Solid Tumor 2Adenoma, Islet Cell 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Rhabdoid Tumor 1Resectable Pancreatic Cancer 1

Interventions

Carboplatin 75Paclitaxel 68Bevacizumab 44Taxes 22Cyclophosphamide 21pembrolizumab 19Gemcitabine 19Cisplatin 18Topotecan 17Hyperthermic Intraperitoneal Chemotherapy 14olaparib 13liposomal doxorubicin 13Immunoglobulin G 13Disulfides 13Specimen Handling 11Drug Therapy 11niraparib 10Cytoreduction Surgical Procedures 10Magnetic Resonance Spectroscopy 9sargramostim 7Surveys and Questionnaires 7Doxorubicin 7Docetaxel 7durvalumab 6Platinum 6Nivolumab 6Letrozole 6Granulocyte-Macrophage Colony-Stimulating Factor 6Biopsy 6Albumin-Bound Paclitaxel 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Fallopian Tube Neoplasms × Colony-Stimulating Factors × Clear all
NCT02470559 2016-02-17

Activated T-cell Therapy, Low-Dose Aldesleukin, and Sargramostim in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That is Stage III-IV, Refractory, or Recurrent

Barbara Ann Karmanos Cancer Institute

Phase 1 Withdrawn
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡